GU Cancers 2024 | OS sensitivity analysis of darolutamide, docetaxel and ADT in ARASENS

Neal Shore, MD, FACS, Carolina Urologic Research Center, Myrtle Beach, SC, comments on findings from the Phase II ARASENS study (NCT02799602) of darolutamide with androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC). A post hoc sensitivity analysis of overall survival (OS) demonstrated that the investigational therapy significantly improved OS compared to placebo. Consistency in sensitivity analyses supports the triplet therapy as an effective and well-tolerated standard of care for early treatment intensification in mHSPC. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.